• AZAZ
  • RURU
AEM
+994 12 596 05 20
Write us
No Result
View All Result
  • About Us
  • Import
    • Documents
    • Letter samples
  • Control
    • Control on Medicines
    • Legislation
  • Registration
    • Department of Registration
    • Legislation
  • Laboratory
    • About the Quality Control Laboratory
  • Pharmacovigilance
    • General information
    • Legislation
    • Information for healthcare professionals
    • Information for Patients
    • Pharmacovigilance dictionary
    • Reporting forms
    • Online reporting
    • For MAH
    • Medicines under additional monitoring
  • Private medical institutions
    • Legislation
  • FS
    • Expertise of FS
    • Result of the Expertise of FS
  • Medical devices
    • Application form
    • MD Documents
    • Results of examination of medical devices
    • Legislation
  • MD monitoring
    • Tracking and Tracing of Medicines Department
AEM
No Result
View All Result

FDA has requested to update the safety information of opioid medicines

May 2, 2023
A A

The US Food and Drug Administration (FDA) has announced that it will require opioid (painkiller) medicine manufacturers to include new safety warnings in the instructions for use of these medicines.

The FDA says, citing reports that patients who take opioid medications for pain relief after surgery often have extra pills left over, which can increase the risk of addiction and even overdose.

Updated safety warnings for these medicines should include information on which patients to prescribe opioid pain medications, the appropriate dose and how to administer them, and how to deal with leftover pills.

Also, on the new packaging, there should be a warning about the risk of overdosing as the dose increases and that opioids should not be used for long periods if the patient’s pain is relieved.

Becker’s Hopsital Review reports that the FDA’s move is part of the agency’s public education program to combat the nation’s opioid crisis and prevent addiction to such medicines.

Source: https://pharmvestnik.ru/content/news/FDA-potrebuet-obnovit-informaciu-o-bezopasnosti-opioidnyh-preparatov

ShareTweetShare
AEM

© 2022 AEM - Analitik Ekspertiza Mərkəzi .

Useful links

  • About Us
  • Contact
  • Rates

Follow us

  • AZAZ
  • RURU
No Result
View All Result
  • About Us
  • Import
    • Documents
    • Letter samples
  • Control
    • Control on Medicines
    • Legislation
  • Registration
    • Department of Registration
    • Legislation
  • Laboratory
    • About the Quality Control Laboratory
  • Pharmacovigilance
    • General information
    • Legislation
    • Information for healthcare professionals
    • Information for Patients
    • Pharmacovigilance dictionary
    • Reporting forms
    • Online reporting
    • Contacts
    • For MAH
    • Medicines under additional monitoring
  • Private medical institutions
    • Legislation
  • FS
    • Expertise of FS
    • Result of the Expertise of FS
  • Medical devices
    • Application form
    • MD Documents
    • Results of examination of medical devices
    • Legislation
  • Rates
  • Contact

© 2022 AEM - Analitik Ekspertiza Mərkəzi .

Accessibility

Content Scaling
Default
Text Magnifier
Dyslexia Friendly
Highlight Links
Font Sizing
Default
Left Aligned
Center Aligned
Right Aligned
Dark Contrast
Monochrome
High Saturation
Adjust Text Colors
Adjust Title Colors
Adjust Background Colors
Hide Images
Reading Guide
Reading Mask
Highlight Hover
Big Dark Cursor
Big Light Cursor